PMID- 26210162 OWN - NLM STAT- MEDLINE DCOM- 20160317 LR - 20181113 IS - 1756-0500 (Electronic) IS - 1756-0500 (Linking) VI - 8 DP - 2015 Jul 26 TI - Assessment of adverse events via a telephone consultation service for cancer patients receiving ambulatory chemotherapy. PG - 315 LID - 10.1186/s13104-015-1292-8 [doi] LID - 315 AB - BACKGROUND: An increasing number of cancer patients are receiving ambulatory chemotherapy to improve their quality of life and reduce medical expenses. During outpatient chemotherapy, adverse events (AEs) occurring at home must be carefully monitored. We investigated the use of our institution's telephone consultation service that is available to patients and their caregivers for advice on and the management of AEs and complications arising from cancer treatment. PATIENTS AND METHODS: Telephone consultants assessed and graded AEs according to the Common Terminology Criteria for Adverse Events (CTCAE). All patient characteristics, AEs, and background factors were analyzed using logistic regression analyses. RESULTS: Between August 2011 and August 2012, we included 253 patients and 344 telephone consultations regarding AEs during chemotherapy for analysis in this study. Grade 1 AEs were assessed in 223 consultations (65%); grade 2 AEs, in 90 consultations (26%); and grade 3 AEs, in 31 consultations (9%). A multivariate logistic regression analysis revealed an association between a change in patient schedules and the occurrence of grade 2 or worse AEs (Hazard ratio = 6.58, P < 0.001). Changes in planned chemotherapy occurred more often in cases involving male patients (Hazard ratio = 2.70, P = 0.02) and in cases of grade 2 or worse AEs (Hazard ratio = 6.58, P < 0.001). CONCLUSION: We found that AE assessment using CTCAE via a telephone consultation service is useful for both the triage of patients and the prediction of severe AEs that may change clinical schedules. FAU - Kondo, Shunsuke AU - Kondo S AD - Outpatient Treatment Center, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. shkondo@ncc.go.jp. FAU - Shiba, Satoshi AU - Shiba S AD - Outpatient Treatment Center, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. sashiba@ncc.go.jp. FAU - Udagawa, Ryoko AU - Udagawa R AD - Outpatient Treatment Center, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. ryudagaw@east.ncc.go.jp. FAU - Ryushima, Yasuaki AU - Ryushima Y AD - Outpatient Treatment Center, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. yryshim@east.ncc.go.jp. FAU - Yano, Miho AU - Yano M AD - Outpatient Treatment Center, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. mhsuzuki@ncc.go.jp. FAU - Uehara, Tomoko AU - Uehara T AD - Outpatient Treatment Center, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. tmuehara@ncc.go.jp. FAU - Asanabe, Mihoko AU - Asanabe M AD - Outpatient Treatment Center, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. masanabe@ncc.go.jp. FAU - Tamura, Kenji AU - Tamura K AD - Outpatient Treatment Center, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. ketamura@ncc.go.jp. FAU - Hashimoto, Jun AU - Hashimoto J AD - Outpatient Treatment Center, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan. juhashim@ncc.go.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150726 PL - England TA - BMC Res Notes JT - BMC research notes JID - 101462768 RN - 0 (Antineoplastic Agents) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/administration & dosage/*adverse effects MH - Disease Management MH - Drug Administration Schedule MH - Female MH - Humans MH - Logistic Models MH - Male MH - Middle Aged MH - Neoplasms/drug therapy/pathology/*psychology MH - Outpatients MH - Quality of Life/*psychology MH - Referral and Consultation/*statistics & numerical data MH - Telephone MH - Triage/*statistics & numerical data PMC - PMC4514970 EDAT- 2015/07/27 06:00 MHDA- 2016/03/18 06:00 PMCR- 2015/07/26 CRDT- 2015/07/27 06:00 PHST- 2014/05/20 00:00 [received] PHST- 2015/07/22 00:00 [accepted] PHST- 2015/07/27 06:00 [entrez] PHST- 2015/07/27 06:00 [pubmed] PHST- 2016/03/18 06:00 [medline] PHST- 2015/07/26 00:00 [pmc-release] AID - 10.1186/s13104-015-1292-8 [pii] AID - 1292 [pii] AID - 10.1186/s13104-015-1292-8 [doi] PST - epublish SO - BMC Res Notes. 2015 Jul 26;8:315. doi: 10.1186/s13104-015-1292-8.